Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer

Combination immunotherapy for melanoma improves long-term survival rates

Research has shown that the five-year survival rate of patients treated with both ipilimumab and nivolumab for advanced melanoma is 52%.

Melanoma on skin

Both the five-year overall survival rate and five-year progression-free survival rate were higher for patients treated with a combination of ipilimumab and nivolumab.

Patients with advanced melanoma treated with a combination of two immunotherapy drugs — ipilimumab and nivolumab — are more likely to be alive five years later than patients treated with ipilimumab alone or nivolumab alone, according to a study published in the New England Journal of Medicine (17 October 2019)[1].

Researchers randomly assigned 945 patients with advanced melanoma to nivolumab plus ipilimumab, nivolumab plus placebo, or ipilimumab plus placebo.

Treatment was administered until the disease progressed or until side effects became unacceptable.

The five-year overall survival rate for nivolumab plus ipilimumab was 52%, compared with 44% for nivolumab plus placebo and 26% for ipilimumab plus placebo. The five-year progression-free survival rate was 36% for patients taking nivolumab plus ipilimumab, 29% for patients taking nivolumab plus placebo, and and 8% for patients taking ipilimumab plus placebo.

“In the past, metastatic melanoma was regarded as untreatable,” said James Larkin, consultant medical oncologist at The Royal Marsden NHS Foundation Trust, London.

“This is the first time we can say that the chances of being a long-term survivor of advanced melanoma are now over 50%, which is a huge milestone.”

The researchers pointed out that patients taking nivolumab plus ipilimumab, who stopped treatment early because of side effects, had similar survival outcomes at five years as the overall population.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207332

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Further MCQs in Pharmacy Practice

    Further MCQs in Pharmacy Practice

    Further MCQs in Pharmacy Practice contains 600 practice-oriented pharmacy exam questions. Includes both open- and closed-book sections.

    £30.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.